Table 1 Clinicopathological features of patients with RAS mutations
From: Emerging strategies to target RAS signaling in human cancer therapy
| Tumor type | N | RAS mutation | Mutation rate | Mutation site | Clinicopathologic features | References |
|---|---|---|---|---|---|---|
| Melanoma | 912 | NRAS | 13.0% | Codon 12, 13, 61 | Presence of mitoses; lower TIL grade; anatomic site other than scalp/necks | [39] |
| Thyroid cancer | 107 | HRAS, NRAS, KRAS | 32.7% | NM | Poorly or undifferentiated type; | [31] |
| mCRC | 484 | KRAS, NRAS | 51.6% | Codon 12, 13, 61, 146 | More mucinous type; higher lung metastases tendency; right-side preference of primary tumors | [206] |
| CRC | 926 | KRAS | 14.7% | Codon 12, 13 | Villous histology preference; advanced adenomas; older age | [207] |
| NSCLC | 6583 | KRAS | 9.2% | Codon 12, 13 | More mucinous type; frequent poorly-differentiated grade; solid pattern tumors preference; larger sized tumors | [208] |
| IMA | 45 | KRAS | 48.9% | Codon 12 | Located in the lower lung lobe; lower frequency of nuclear atypia; lower proportion of geminin-positive cell | [209] |
| EOC | 153 | KRAS | 11.1% | Codon 12, 13, 61 | More mucinous type; lower differentiation grade; higher PR expression; higher pT classifications | [40] |
| SIA | 190 | KRAS | 32.1% | Codon 12, 13 | More frequent pancreatic invasion | [210] |